Reducing acetylcholine availability using the muscarinic acetylcholine receptor antagonist scopolamine enhances slow wave activity in AD patients [108], while oscillatory slowing is counteracted by acetyl-cholinesterase inhibitors that increase the availability of acetylcholine [109–111]. This evidence concerns the gene ACHE and Alzheimer disease.